Previous 10 | Next 10 |
SAB Biotherapeutics (NASDAQ:SABS) said the National Institutes of Health (NIH) is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable. SAB-185 was being evaluated as part o...
NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study design statistically unworkable SAB-185 had advanced into Phase 3 after meeting pre-specified efficacy and safety criteria SA...
In the FDA-conducted study , SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed convalescent plasma Findings published in The Jo...
SAB Biotherapeutics (NASDAQ:SABS) updated the design of its ongoing phase 3 ACTIV-2 trial evaluating SAB-185 to treat people with mild-moderate COVID infections at higher risk for progression to hospitalization. The Phase 3 trial had been designed as non-inferiority study comparing SAB-185 to...
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that pro...
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700 patients have been enrolled in the Phase 3 trial, exceeding 50% enrollment ...
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human dono...
SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, tod...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday! Source: Shutterstock We’ve got an FDA update, several agreements...
SAB Biotherapeutics (NASDAQ:SABS) soars 19% premarket after announcing data, demonstrating that SAB-185, a therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The res...
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
SAB Biotherapeutics Inc. Website:
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is one of today's top gainers. The company's shares have moved 0% on the day to $2.77. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advance...
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB...
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progre...